Abstract
Temozolomide is an alkylating agent used frequently in the management of gliomas. Although temozolomide is generally safe, rarely it can cause life threatening complications. Here we report the cases of two patients who developed prolonged and severe pancytopenia after low dose continuous temozolomide concurrently with cranial radiotherapy. The pancytopenia lasted two to six months. Both the patients were young, treatment naïve, and had temozolomide treatment for only approximately four weeks.
References
Stupp R, Mason WP, van den Bent MJ et al (2005) radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
Spence AM, Kiem HP, Partap S, Schuetze S, Silber JR, Peterson RA (2006) Complications of a temozolomide overdose: a case report. J Neuro-Oncol 80:57–61
Hartmann P, Herholz K, Salzberger B, Petereit HF (2004) Unusual and severe symptomatic impairment of neutrophil function after one cycle of temozolomide in patients with malignant gliomas. Ann Hematol 83:212–217
Su YW, Chang MC, Chiang MF, Hsieh RK (2005) Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neuro-Oncol 71(3):315–318
Noronha V, Berliner N, Ballen KK, Lacy J, Kracher J, Baehring J, Henson JW (2006) Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro-oncol 8(3):280–283
Doyle TJ, Mikkelsen T, Croteau D et al (2005) Fatal hematologic toxicity with prolonged continuous administration of temozolomide (TMZ) during radiation therapy (RT) in the treatment of newly-diagnosed glioblastoma multiforme (GBM): Report of a Phase II trial. J Clin Oncol, ASCO Annual Meeting Proceedings 23 (16S):1546
Villano JL, Collins CA, Manasanch EE et al (2006) Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 7:436–438
Fink D, Aebi S, Howell SB (1998) The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4:1–6
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Singhal, N., Selva-Nayagam, S. & Brown, M.P. Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature. J Neurooncol 85, 229–230 (2007). https://doi.org/10.1007/s11060-007-9403-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-007-9403-6